文献速递肾移植

应用动脉C4d免疫过氧化物酶诊断的抗体介导性血管排斥反应的临床与病理表型

The Clinical and Pathologic Phenotype of Antibody-Mediated Vascular Rejection Diagnosed Using Arterial C4d Immunoperoxidase.
PubMed 文献 · Kidney Int Rep · 2022-05-05

在单中心3309例连续肾移植活检中,100例血管排斥反应(VR)与无动脉炎的排斥反应(n=540)及正常对照(n=1108)比较,评估动脉C4d(C4dart)免疫过氧化物酶沉积对诊断和分类抗体介导性血管排斥反应(AM-VR)的临床效用。将C4dart加入Banff抗体介导排斥反应(AMR)方案后,AM-VR诊断敏感性从57.9%升至93.0%,准确性从74.0%升至92.0%,特异性从95.4%降至90.2%。

要点

  • C4dart见于20.4%的急性、11.0%的亚临床和46%的VR发作。
  • 半定量C4dart评分与免疫优势供者特异性抗体(DSA)显著相关(rho=0.500,P<0.001)。
  • C4dart AM-VR标准与死亡删失的移植肾衰竭相关(校正HR 4.310,95%CI 1.322-14.052,P=0.015)。

核心结论

  • C4dart是提示针对肌性动脉的体液同种免疫反应的生物标志物。
  • 将C4dart纳入Banff方案改善了检测AM-VR的诊断性能及动脉炎的病因学分类。

研究设计与样本

  • 单中心连续3309例肾移植活检中,100例血管排斥反应(VR)与无动脉炎的排斥反应(n=540)及正常对照(n=1108)比较。
  • 以独立参考试验评估C4dart对AM-VR诊断和分类的临床效用。

主要发现

  • C4dart见于20.4%的急性、11.0%的亚临床和46%的VR发作。
  • 半定量C4dart评分与免疫优势DSA(rho=0.500,P<0.001)、管周毛细血管C4d(C4dptc)、微血管炎症和Banff v评分显著相关。
  • Banff v3动脉炎提示AM-VR。
  • 与Banff 2019(使用C4dptc)相比,将C4dart加入Banff AMR方案使AM-VR诊断敏感性从57.9%升至93.0%,准确性从74.0%升至92.0%,特异性从95.4%降至90.2%。
  • Cox回归显示C4dart AM-VR标准与死亡删失的移植肾衰竭相关(校正HR 4.310,95%CI 1.322-14.052,P=0.015)。

关键数值与推荐

  • VR按病因分为AM-VR(n=57,包括36例混合性VR)或「单纯性」TCM-VR(n=43)。
  • 与TCM-VR相比,AM-VR发生于所有移植后时期,特征为更高的总体、间质和微血管炎症、动脉和管周C4d、DSA水平及移植肾衰竭率。
  • 混合性VR肾脏具有最大的炎症负荷和移植肾丢失(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The diagnosis of antibody-mediated vascular rejection (AM-VR) should be reliable and accurate. We hypothesized that arterial C4d (C4dart) immunoperoxidase deposition represents endothelial interaction with antibody. METHODS: From 3309 consecutive, kidney transplant biopsies from a single center, 100 vascular rejection (VR) cases were compared against rejection without arteritis (n = 540) and normal controls (n = 1108). The clinical utility of C4dart for diagnosis and classification of AM-VR was evaluated against an independent reference test. RESULTS: C4dart occurred in 20.4% of acute, 11.0% of subclinical, and 46% of VR episodes. Semiquantitative C4dart score significantly correlated with immunodominant donor-specific antibodies (DSAs) (rho = 0.500, P < 0.001), peritubular capillary C4d (C4dptc), microvascular inflammation, and Banff v scores. Banff v3 arteritis suggested AM-VR. Addition of C4dart to Banff antibody-mediated rejection (AMR) schema increased diagnostic sensitivity for AM-VR from 57.9% to 93.0%, accuracy 74.0% to 92.0%, and specificity 95.4% to 90.2% versus Banff 2019 (using C4dptc). Death-censored graft failure was associated with C4dart AM-VR criteria using Cox regression (adjusted hazard ratio [HR] 4.310, 95% CI 1.322-14.052, P = 0.015). VR was then etiologically classified into AM-VR (n = 57, including 36 mixed VR) or "pure" (TCM-VR, n = 43). AM-VR occurred within all post-transplant periods, characterized by greater total, interstitial, and microvascular inflammation, arterial and peritubular C4d, DSA levels, and graft failure rates compared with TCM-VR. Mixed VR kidneys had the greatest inflammatory burden and graft loss (P < 0.001). CONCLUSION: C4dart is a suggestive biomarker of the humoral alloresponse toward muscular arteries. Inclusion of C4dart into the Banff schema improved its diagnostic performance for detection of AM-VR and etiologic classification of arteritis.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Nankivell BJ, Shingde M, P'Ng CH, et al. The Clinical and Pathologic Phenotype of Antibody-Mediated Vascular Rejection Diagnosed Using Arterial C4d Immunoperoxidase. Kidney Int Rep. 2022. PMID: 35812292. doi:10.1016/j.ekir.2022.04.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。